<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="" /><meta name="keywords" content="Antituberculous drugs; Tuberculosis; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Streptomycin; Rifater; Ethambutol; Rifinah; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; DOT (directly observed therapy); Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Mycobacterium avium complex infections; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Rifamycins; Rifabutin; Pyrazinamide; Ethambutol; Streptomycin; Amikacin: tuberculosis; Capreomycin; Cycloserine; Prothionamide see Protionamide; Protionamide" /><meta name="IX" content="Antituberculous drugs; Tuberculosis; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Streptomycin; Rifater; Ethambutol; Rifinah; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; DOT (directly observed therapy); Isoniazid; Rifamycins; Rifampicin: tuberculosis; Pyrazinamide; Ethambutol; Mycobacterium avium complex infections; Isoniazid; Rifamycins; Rifampicin: tuberculosis; Rifamycins; Rifabutin; Pyrazinamide; Ethambutol; Streptomycin; Amikacin: tuberculosis; Capreomycin; Cycloserine; Protionamide" /><meta name="IXN" content="Prothionamide see Protionamide" /><title>5.1.9 Antituberculosis drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP3588-antituberculosis-drugs.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP3588-antituberculosis-drugs.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP3588-antituberculosis-drugs.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP3253-infections.htm">5 Infections</a> &gt; <a href="PHP3256-antibacterial-drugs.htm">5.1 Antibacterial drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP3586-trimethoprim.htm" title="Previous: TRIMETHOPRIM">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP3599-capreomycin.htm" title="Next: CAPREOMYCIN">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1><span>5.1.9 </span>Antituberculosis drugs</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h3 class="cO">Additional information</h3> <p class="cT"> interactions (<a href="bnf_int199-rifamycins.htm">Rifamycins</a>).</p></div></div><p>Tuberculosis is treated in two phases—an <em>initial phase</em> using 4 drugs and a <em>continuation phase</em> using 2 drugs in fully sensitive cases. Treatment requires specialised knowledge, particularly where the disease involves resistant organisms or non-respiratory organs.</p> <p>The regimens given below are recommended for the treatment of tuberculosis in the UK; variations occur in other countries. Either the unsupervised regimen or the supervised regimen described below should be used; the two regimens should <strong>not</strong> be used concurrently. </p> <div><h2>Initial phase</h2><p>The concurrent use of 4 drugs during the initial phase is designed to reduce the bacterial population as rapidly as possible and to prevent the emergence of drug-resistant bacteria. The drugs are best given as combination preparations unless one of the components cannot be given because of resistance or intolerance. The treatment of choice for the initial phase is the daily use of isoniazid, rifampicin, pyrazinamide and ethambutol. Treatment should be started without waiting for culture results if clinical features or histology results are consistent with tuberculosis; treatment should be continued even if initial culture results are negative. The initial phase drugs should be continued for 2 months. Where a positive culture for <em>M. tuberculosis</em> has been obtained, but susceptibility results are not available after 2 months, treatment with rifampicin, isoniazid, pyrazinamide and ethambutol should be continued until full susceptibility is confirmed, even if this is for longer than 2 months.</p><p>Streptomycin is rarely used in the UK but it may be used in the initial phase of treatment if resistance to isoniazid has been established before therapy is commenced.</p></div> <div><h2>Continuation phase</h2><p>After the initial phase, treatment is continued for a further 4 months with isoniazid and rifampicin (preferably given as a combination preparation). Longer treatment is necessary for meningitis, direct spinal cord involvement, and for resistant organisms which may also require modification of the regimen.</p></div> <div><h2>Unsupervised treatment</h2><p>The following regimen should be used for patients who are likely to take antituberculous drugs reliably <strong>without supervision</strong>. Patients who are unlikely to comply with daily administration of antituberculous drugs should be treated with the regimen described under Supervised Treatment. </p></div> <div class="table" id="PHP3589"> <div class="cAA">Recommended dosage for standard unsupervised 6-month treatment</div> <table class="table" summary="Recommended dosage for standard unsupervised 6-month treatment" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><tbody><tr><td style="" colspan="2"><em>2-month initial phase</em></td></tr><tr><td style=""> </td><td class="auto-generated" style=""> </td></tr><tr><td style=""><em><strong>Rifater</strong>®</em> [rifampicin, isoniazid, and pyrazinamide]</td><td style=""><span class="cP">adult</span> body-weight under 40 kg 3 tablets daily; body-weight 40–49 kg 4 tablets daily; body-weight 50–64 kg 5 tablets daily; body-weight over 65 kg 6 tablets daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Ethambutol </strong></td><td style=""><span class="cP">adult</span> and <span class="cP">child</span> 15 mg/kg daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style="" colspan="2"><em>4-month continuation phase following initial treatment with Rifater® and ethambutol</em></td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><em><strong>Rifinah</strong>®</em>[rifampicin and isoniazid]</td><td style=""><span class="cP">adult</span> body-weight under 50 kg 3 tablets daily of <em>Rifinah</em>® <em>150/100</em>; body-weight 50 kg and over 2 tablets daily of <em>Rifinah</em>® <em>300/150</em></td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style="" colspan="2"><em>or</em> (if combination preparations not appropriate):</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Isoniazid</strong> (for 6 months)</td><td style=""><span class="cP">adult</span> 300 mg daily; <span class="cP">child</span> 10 mg/kg (max. 300 mg) daily</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Rifampicin</strong> (for 6 months)</td><td style=""><span class="cP">adult</span> body-weight under 50 kg 450 mg daily; body-weight 50 kg and over 600 mg daily; <span class="cP">child</span> 10 mg/kg daily (max. 450 mg daily if body-weight under 50 kg; max. 600 mg daily if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Pyrazinamide</strong> (for 2-month initial phase only)</td><td style=""><span class="cP">adult</span> body-weight under 50 kg 1.5 g daily; body-weight 50 kg and over 2 g daily; <span class="cP">child</span> 35 mg/kg daily (max. 1.5 g daily if body-weight under 50 kg; max. 2 g daily if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Ethambutol</strong> (for 2-month initial phase only)</td><td style=""><span class="cP">adult</span> and <span class="cP">child</span> 15 mg/kg daily</td></tr></tbody></table></div> <div id="PHP3590"><h2>Pregnancy</h2><p>The standard regimen (above) may be used during pregnancy. Streptomycin should not be given in pregnancy.</p></div> <div id="PHP3591"><h2>Breast-feeding</h2><p>The standard regimen (above) may be used during breast-feeding</p></div> <div><h2>Children</h2><p>Children are given isoniazid, rifampicin, pyrazinamide, and ethambutol for the first 2 months followed by isoniazid and rifampicin during the next 4 months. However, care is needed in young children receiving ethambutol because of the difficulty in testing eyesight and in obtaining reports of visual symptoms (see below).</p></div> <div><h2>Supervised treatment</h2><p>Drug administration needs to be <strong>fully supervised</strong> (directly observed therapy, DOT) in patients who cannot comply reliably with the treatment regimen. These patients are given isoniazid, rifampicin, pyrazinamide and ethambutol (or streptomycin) 3 times a week under supervision for the first 2 months followed by isoniazid and rifampicin 3 times a week for a further 4 months.</p></div> <div class="table" id="PHP3592"> <div class="cAA">Recommended dosage for intermittent supervised 6-month treatment</div> <table class="table" summary="Recommended dosage for intermittent supervised 6-month treatment" cellspacing="0" cellpadding="8" border="0" style="border-collapse: collapse;border-top: 1pt solid ; border-bottom: 1pt solid ; "><colgroup><col /><col /></colgroup><tbody><tr><td style=""><strong>Isoniazid</strong> (for 6 months)</td><td style=""><span class="cP">adult</span> and <span class="cP">child</span> 15 mg/kg (max. 900 mg) 3 times a week</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Rifampicin</strong> (for 6 months)</td><td style=""><span class="cP">adult</span> 600–900 mg 3 times a week; <span class="cP">child</span> 15 mg/kg (max. 900 mg) 3 times a week</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Pyrazinamide</strong> (for 2-month initial phase only)</td><td style=""><span class="cP">adult</span> body-weight under 50 kg 2 g 3 times a week; body-weight 50 kg and over 2.5 g 3 times a week; <span class="cP">child</span> 50 mg/kg 3 times a week (max. 2 g 3 times a week if body-weight under 50 kg; max. 2.5 g 3 times a week if body-weight 50 kg and over)</td></tr><tr><td style=""> </td><td style=""> </td></tr><tr><td style=""><strong>Ethambutol</strong> (for 2-month initial phase only)</td><td style=""><span class="cP">adult</span> and <span class="cP">child</span> 30 mg/kg 3 times a week</td></tr></tbody></table></div> <div><h2>Immunocompromised patients</h2><p>Multi-resistant <em>Mycobacterium tuberculosis</em> may be present in immunocompromised patients. The organism should always be cultured to confirm its type and drug sensitivity. Confirmed <em>M. tuberculosis</em> infection sensitive to first-line drugs should be treated with a standard 6-month regimen; after completing treatment, patients should be closely monitored. The regimen may need to be modified if infection is caused by resistant organisms, and specialist advice is needed.</p><p>Specialist advice should be sought about tuberculosis treatment or chemoprophylaxis in a HIV-positive individual; care is required in choosing the regimen and in avoiding potentially serious interactions. Starting antiretroviral treatment in the first 2 months of antituberculosis treatment increases the risk of immune reconstitution syndrome.</p><p>Infection may also be caused by other mycobacteria e.g. <em>M. avium</em> complex in which case specialist advice on management is needed.</p></div> <div><h2>Corticosteroids</h2><p>In meningeal or pericardial tuberculosis, a corticosteroid should be started at the same time as antituberculosis therapy. </p></div> <div><h2>Prevention of tuberculosis</h2><p>Some individuals may develop tuberculosis owing to reactivation of previously latent disease. Chemoprophylaxis may be required in those who have evidence of latent tuberculosis and are receiving treatment with immunosuppressants (including cytotoxics and possibly long-term treatment with systemic corticosteroids). In these cases, chemoprophylaxis involves use of either isoniazid alone for 6 months or of isoniazid and rifampicin for 3 months, see Table 2, <a title="sub-topic: Table 2 TB prophylaxis" href="PHP3285-prevention-of-tuberculosis-in-susceptible-close-contacts-or-those-who-have-become-tuberculin-positive.htm"> section 5.1</a>; longer chemoprophylaxis is not recommended. </p><p>For prevention of tuberculosis in susceptible close contacts or those who have become tuberculin-positive, see Table 2, <a title="sub-topic: Table 2 TB prophylaxis" href="PHP3285-prevention-of-tuberculosis-in-susceptible-close-contacts-or-those-who-have-become-tuberculin-positive.htm">section 5.1</a>. For advice on immunisation against tuberculosis, see <a title="monograph-family: BCG vaccines" href="PHP8247-bcg-vaccines.htm">section 14.4</a></p></div> <div id="PHP3593"><h2>Monitoring</h2><p>Since isoniazid, rifampicin and pyrazinamide are associated with liver toxicity, <em>hepatic function</em> should be checked before treatment with these drugs. Those with pre-existing liver disease or alcohol dependence should have frequent checks particularly in the first 2 months. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. In view of the need to comply fully with antituberculous treatment on the one hand and to guard against serious liver damage on the other, patients and their carers should be informed carefully how to recognise signs of liver disorders and advised to discontinue treatment and seek <strong>immediate</strong> medical attention should symptoms of liver disease occur.</p><p><em>Renal function</em> should be checked before treatment with antituberculous drugs and appropriate dosage adjustments made. Streptomycin or ethambutol should preferably be avoided in patients with renal impairment, but if used, the dose should be reduced and the plasma-drug concentration monitored.</p><p><em>Visual acuity</em> should be tested before ethambutol is used (see below).</p></div> <div class="cI"><p>Major causes of treatment failure are incorrect prescribing by the physician and inadequate compliance by the patient. Monthly tablet counts and urine examination (rifampicin imparts an orange-red coloration) may be useful indicators of compliance with treatment. Avoid both excessive and inadequate dosage. Treatment should be supervised by a specialist physician.</p></div> <p id="PHP3594"><strong>Isoniazid</strong> is cheap and highly effective. Like rifampicin it should always be included in any antituberculous regimen unless there is a specific contra-indication. Its only common side-effect is peripheral neuropathy which is more likely to occur where there are pre-existing risk factors such as diabetes, alcohol dependence, chronic renal failure, pregnancy, malnutrition and HIV infection. In these circumstances pyridoxine 10 mg daily (or 20 mg daily if suitable product not available) (<a title=" Vitamin B group" href="PHP6196-vitamin-b-group.htm">section 9.6.2</a>) should be given prophylactically from the start of treatment. Other side-effects such as hepatitis (important: see Monitoring above) and psychosis are rare.</p> <p><strong>Rifampicin</strong>, a rifamycin, is a key component of any antituberculous regimen. Like isoniazid it should always be included unless there is a specific contra-indication.</p> <p id="PHP3595">During the first two months (‘initial phase’) of rifampicin administration transient disturbance of liver function with elevated serum transaminases is common but generally does not require interruption of treatment. Occasionally more serious liver toxicity requires a change of treatment particularly in those with pre-existing liver disease (important: see Monitoring above).</p> <p>On intermittent treatment six toxicity syndromes have been recognised—influenza-like, abdominal, and respiratory symptoms, shock, renal failure, and thrombocytopenic purpura—and can occur in 20 to 30% of patients.</p> <p>Rifampicin induces hepatic enzymes which accelerate the metabolism of several drugs including oestrogens, corticosteroids, phenytoin, sulfonylureas, and anticoagulants; <strong>interactions:</strong> Appendix 1 (rifamycins). <strong>Important:</strong> the effectiveness of hormonal contraceptives is reduced and alternative family planning advice should be offered (<a title=" Combined oral contraceptives" href="PHP4869-combined-hormonal-contraceptives.htm">section 7.3.1</a>).</p> <p><strong>Rifabutin</strong>, another rifamycin, is indicated for <em>prophylaxis</em> against <em>M. avium</em> complex infections in patients with a low CD4 count; it is also licensed for the <em>treatment</em> of non-tuberculous mycobacterial disease and pulmonary tuberculosis. <strong>Important:</strong> as with rifampicin it induces hepatic enzymes and the effectiveness of hormonal contraceptives is reduced requiring alternative family planning methods.</p> <p><strong>Pyrazinamide</strong> [unlicensed] is a bactericidal drug only active against intracellular dividing forms of <em>Mycobacterium tuberculosis</em>; it exerts its main effect only in the first two or three months. It is particularly useful in tuberculous meningitis because of good meningeal penetration. It is not active against <em>M. bovis</em>. Serious liver toxicity may occasionally occur (important: see Monitoring above).</p> <p><strong>Ethambutol</strong> is included in a treatment regimen if isoniazid resistance is suspected; it can be omitted if the risk of resistance is low. </p> <p id="PHP3596">Side-effects of ethambutol are largely confined to visual disturbances in the form of loss of acuity, colour blindness, and restriction of visual fields. These toxic effects are more common where excessive dosage is used or if the patient's renal function is impaired. The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vision and promptly seek further advice. Early discontinuation of the drug is almost always followed by recovery of eyesight. Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.</p> <p>Visual acuity should be tested by Snellen chart before treatment with ethambutol.</p> <p id="PHP3597"><strong>Streptomycin</strong> [unlicensed] is now rarely used in the UK except for resistant organisms. Plasma-drug concentration should be measured in patients with impaired renal function in whom streptomycin must be used with great care.</p> <p>Drug-resistant tuberculosis should be treated by a specialist physician with experience in such cases, and where appropriate facilities for infection-control exist. Second-line drugs available for infections caused by resistant organisms, or when first-line drugs cause unacceptable side-effects, include amikacin, capreomycin, cycloserine, newer macrolides (e.g. azithromycin and clarithromycin), moxifloxacin and protionamide (prothionamide; no longer on UK market).</p> </div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP3599-capreomycin"><a href="PHP3599-capreomycin.htm" title="CAPREOMYCIN">CAPREOMYCIN</a></li><li id="_PHP3602-cycloserine"><a href="PHP3602-cycloserine.htm" title="CYCLOSERINE">CYCLOSERINE</a></li><li id="_PHP3604-ethambutol-hydrochloride"><a href="PHP3604-ethambutol-hydrochloride.htm" title="ETHAMBUTOL HYDROCHLORIDE">ETHAMBUTOL HYDROCHLORIDE</a></li><li id="_PHP3608-isoniazid"><a href="PHP3608-isoniazid.htm" title="ISONIAZID">ISONIAZID</a></li><li id="_PHP3612-pyrazinamide"><a href="PHP3612-pyrazinamide.htm" title="PYRAZINAMIDE">PYRAZINAMIDE</a></li><li id="_PHP3616-rifabutin"><a href="PHP3616-rifabutin.htm" title="RIFABUTIN">RIFABUTIN</a></li><li id="_PHP3619-rifampicin"><a href="PHP3619-rifampicin.htm" title="RIFAMPICIN">RIFAMPICIN</a></li><li id="_PHP3631-rifampicin-with-isoniazid"><a href="PHP3631-rifampicin-with-isoniazid.htm" title="RIFAMPICIN WITH ISONIAZID">RIFAMPICIN WITH ISONIAZID</a></li><li id="_PHP3636-streptomycin"><a href="PHP3636-streptomycin.htm" title="STREPTOMYCIN">STREPTOMYCIN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP3586-trimethoprim.htm">Previous: TRIMETHOPRIM</a> | <a class="top" href="PHP3588-antituberculosis-drugs.htm#">Top</a> | <a accesskey="]" href="PHP3599-capreomycin.htm">Next: CAPREOMYCIN</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>